BR0213175A - Forma galênica oral macroparticular para a liberação retardada e controlada de princìpios ativos farmacêuticos - Google Patents

Forma galênica oral macroparticular para a liberação retardada e controlada de princìpios ativos farmacêuticos

Info

Publication number
BR0213175A
BR0213175A BR0213175-7A BR0213175A BR0213175A BR 0213175 A BR0213175 A BR 0213175A BR 0213175 A BR0213175 A BR 0213175A BR 0213175 A BR0213175 A BR 0213175A
Authority
BR
Brazil
Prior art keywords
release
delayed
controlled release
macroparticular
dosage form
Prior art date
Application number
BR0213175-7A
Other languages
English (en)
Other versions
BRPI0213175B8 (pt
BRPI0213175B1 (pt
Inventor
Valerie Legrand
Catherine Castan
Remi Meyrueix
Gerard Soula
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of BR0213175A publication Critical patent/BR0213175A/pt
Publication of BRPI0213175B1 publication Critical patent/BRPI0213175B1/pt
Publication of BRPI0213175B8 publication Critical patent/BRPI0213175B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMA GALêNICA ORAL MACROPARTICULAR PARA A LIBERAçãO RETARDADA E CONTROLADA DE PRINCìPIOS ATIVOS FARMACêUTICOS". A invenção se refere a um sistema microparticular de liberação retardada controlada de princípios ativos (PA), cuja janela de absorção in vivo é essencialmente limitada nas partes altas do trato gastrointestinal , esse sistema sendo destinado a uma administração por via oral. A finalidade da invenção é de fornecer um sistema que a assegura a liberação do PA de forma contínua de forma certa, graças a um duplo mecanismo de "liberação tempo dependente" e "pH dependente". Para atingir essa finalidade, a invenção propós uma forma galênica oral multimicrocapsular concebida de tal modo que sua eficácia terapêutica seja garantida, e na qual a liberação do PA é regida por um duplo mecanismo de acionamento da liberação: "tempo acionador" e "pH acionador". Esse sistema é constituído de microcápsulas (200 a 600 <109>m) que compreendem um núcleo em PA recoberto de uma película de revestimento (máximo 40% em peso), compreendendo um polímero hidrófilo A (EUDRAGIT<32>L) e um composto B hidrófobo (cera vegetal temperatura de fusão = 40-90<198>C), com B/A compreendido entre 0,2 e 1,5. Essas microcápsulas têm um comportamento de dissolução in vitro tal que tem pH 1,4 constante, se observa uma fase de latência compreendida entre 1 e 5 horas seguida de uma liberação do PA e tal que a passagem de pH 1,4 para 6,8 acarreta uma liberação do PA sem tempo de latência in vitro.
BRPI0213175A 2001-10-09 2002-10-09 forma galênica oral macroparticulada para a liberação retardada e controlada de um princípios ativos farmacêuticos e uso de microcápsulas "reservatório" BRPI0213175B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0112999 2001-10-09
FR0112999A FR2830447B1 (fr) 2001-10-09 2001-10-09 Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
PCT/FR2002/003443 WO2003030878A2 (fr) 2001-10-09 2002-10-09 Forme galenique orale microparticulaire

Publications (3)

Publication Number Publication Date
BR0213175A true BR0213175A (pt) 2004-09-14
BRPI0213175B1 BRPI0213175B1 (pt) 2017-06-20
BRPI0213175B8 BRPI0213175B8 (pt) 2021-05-25

Family

ID=8868097

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213175A BRPI0213175B8 (pt) 2001-10-09 2002-10-09 forma galênica oral macroparticulada para a liberação retardada e controlada de um princípios ativos farmacêuticos e uso de microcápsulas "reservatório"

Country Status (15)

Country Link
US (1) US20050037077A1 (pt)
EP (1) EP1434572B1 (pt)
JP (1) JP4718116B2 (pt)
KR (2) KR20100063825A (pt)
CN (1) CN100341493C (pt)
AU (1) AU2002362712A1 (pt)
BR (1) BRPI0213175B8 (pt)
CA (1) CA2463134C (pt)
ES (1) ES2661723T3 (pt)
FR (1) FR2830447B1 (pt)
HK (1) HK1072898A1 (pt)
IL (2) IL160795A0 (pt)
MX (1) MXPA04003367A (pt)
WO (1) WO2003030878A2 (pt)
ZA (1) ZA200402460B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
EP1608347B1 (en) * 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
CA2581764A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
US20080193537A1 (en) * 2005-05-13 2008-08-14 Alpharma, Inc. Morphine Sulfate Formulations
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008122967A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
WO2010077774A2 (en) 2008-12-17 2010-07-08 Dow Corning Corporation Suspensions of silicate shell microcapsules for temperature controlled release
FR2940619B1 (fr) 2008-12-31 2012-02-10 Flamel Technologies Sa Composition comprenant un actif de solubilite aqueuse faible ou moyenne
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
FR2945947B1 (fr) * 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2945945B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Procede de preparation de particules creuses et leurs applications
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
FR2952936B1 (fr) 2009-11-26 2011-11-25 Flamel Tech Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
SG10201607085WA (en) 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
WO2013035081A2 (de) * 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CA2896864C (en) * 2013-01-05 2021-04-20 Elcelyx Therapeutics, Inc. Delayed-release composition comprising biguanide
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CN105560211B (zh) * 2015-12-30 2019-06-14 大连医诺生物股份有限公司 优化包埋的微囊制剂
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2019129454A1 (en) 2017-12-29 2019-07-04 Unilever N.V. Non-spherical microcapsule
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029884A (en) * 1971-03-18 1977-06-14 Abbott Laboratories Adenosine-5'-carboxylic acid amides
US3864483A (en) * 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US3892769A (en) * 1973-07-20 1975-07-01 Merck & Co Inc Acetaminophen esters of aryl salicylic acids
US3966917A (en) * 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4454309A (en) * 1980-11-12 1984-06-12 Tyndale Plains-Hunter, Ltd. Polyurethane polyene compositions
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4833905A (en) * 1983-06-03 1989-05-30 Micromatic Textron Inc. Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4902513A (en) * 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
JPH0791184B2 (ja) * 1988-03-31 1995-10-04 田辺製薬株式会社 放出制御型製剤およびその製法
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
FR2642080B1 (fr) * 1989-01-23 1992-10-02 Onera (Off Nat Aerospatiale) Polysilanes et leur procede de preparation
US4948581A (en) * 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
SE9002684D0 (sv) * 1990-08-17 1990-08-17 Malvac Foundation C O Peter Pe New peptides and their use
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
FR2704146B1 (fr) * 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
FR2708932B1 (fr) * 1993-08-10 1995-11-10 Flamel Tech Sa Procédé de préparation de polyaminoacides.
DK0758244T4 (da) * 1994-05-06 2008-06-16 Pfizer Doseringsformer af azithromycin med styret frigivelse
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
JP2690276B2 (ja) * 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
US5750468A (en) * 1995-04-10 1998-05-12 Monsanto Company Glyphosate formulations containing etheramine surfactants
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2746035B1 (fr) * 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
JPH10167959A (ja) * 1996-12-04 1998-06-23 Zensei Yakuhin Kogyo Kk ジクロフェナクナトリウムの徐放性カプセル製剤
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
JP2000103732A (ja) * 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd 腸内適所放出型製剤
DE69924735T2 (de) * 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2000050015A1 (en) * 1999-02-23 2000-08-31 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
FR2801226B1 (fr) * 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US7785625B2 (en) * 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
JP3888064B2 (ja) * 2000-01-27 2007-02-28 田辺製薬株式会社 徐放性製剤およびその製法
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US6499158B1 (en) * 2000-10-30 2002-12-31 Steris, Inc. Surgical table top and accessory clamp used thereon
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20050089572A1 (en) * 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
BR0317275A (pt) * 2002-12-11 2005-11-08 Pfizer Prod Inc Liberação controlada de uma substância ativa em um ambiente de gordura alta
JP2004188307A (ja) * 2002-12-11 2004-07-08 Japan Atom Energy Res Inst リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去
PL1842533T3 (pl) * 2003-08-06 2013-08-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
CA2581764A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions

Also Published As

Publication number Publication date
IL160795A (en) 2010-11-30
FR2830447A1 (fr) 2003-04-11
FR2830447B1 (fr) 2004-04-16
ZA200402460B (en) 2005-08-31
CN1568181A (zh) 2005-01-19
KR101078636B1 (ko) 2011-11-01
JP2005506336A (ja) 2005-03-03
BRPI0213175B8 (pt) 2021-05-25
AU2002362712A1 (en) 2003-04-22
WO2003030878A2 (fr) 2003-04-17
EP1434572B1 (fr) 2017-12-13
US20050037077A1 (en) 2005-02-17
IL160795A0 (en) 2004-08-31
KR20040073433A (ko) 2004-08-19
KR20100063825A (ko) 2010-06-11
JP4718116B2 (ja) 2011-07-06
MXPA04003367A (es) 2005-01-25
ES2661723T3 (es) 2018-04-03
BRPI0213175B1 (pt) 2017-06-20
EP1434572A2 (fr) 2004-07-07
CN100341493C (zh) 2007-10-10
CA2463134C (fr) 2012-01-03
WO2003030878A3 (fr) 2003-12-04
HK1072898A1 (en) 2005-09-16
CA2463134A1 (fr) 2003-04-17

Similar Documents

Publication Publication Date Title
BR0213175A (pt) Forma galênica oral macroparticular para a liberação retardada e controlada de princìpios ativos farmacêuticos
ES2265439T3 (es) Formulacion oral de valdecoxib que se desintegra rapidamente.
WO2006056711A3 (fr) Medicament oral a liberation modifiee d&#39;au moins un principe actif sous forme multimicrocapsulaire
ES2283821T3 (es) Composicioon farmaceutica solida que contiene un principio activo lipofilo y su procedimiento de preparacion.
BRPI0414311A (pt) formas de dosagem de liberação controlada
CA3108214A1 (en) Extended release formulations of cannabinoids
AR062167A1 (es) Sistema de administracion gastrorretentivo
ES2292614T3 (es) Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2.
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
Vishal et al. Formulation and evaluation of orodispersible tablets of lornoxicam
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
CO5060477A1 (es) Forma de dosificacion de nefazodona
WO2008035020A3 (fr) Forme galenique pour l&#39;administration par voie trans-muqueuse de principes actifs
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
WO2002024203A3 (en) Controlled release formulations for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
TW200526266A (en) Non-tabletted, chewable, individually dosed administration forms
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
BR0308305A (pt) Fórmulas dosadas de liberação controlada
ES2395740T3 (es) Composiciones que comprenden estroncio y usos de las mismas en el tratamiento o prevención de la gingivitis, la periodontitis, la periodontitis como una manifestacioón de enfermedades sistémicas y las enfermedades peridontales necrotizantes
MA32722B1 (fr) Formulation galénique renfermant de l&#39;aliskirène et procédé associé de préparation par granulation par fusion-extrusion
MX2015002946A (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
EP1631253A1 (en) Sublingual administration of non-steroidal anti-inflammatory pharmacological substances
Gandhi et al. Evaluation of KYRON T-314 (polacrillin potassium) as a novel super disintegrant
DE60041004D1 (de) Abführzusammensetzung,welche l-arginine enthält

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/50, A61K 9/14, A61K 9/22, A61K 9/29, A61K 9/48, A61K 9/50, A61K 9/52, A61P 15/18, A61P 25/00, A61P 29/00, A61P 3/10, A61P 31/04, A61P 31/10, A61P 31/12, A61P 7/02

Ipc: A61K 9/50 (2011.01), A61K 9/14 (2011.01), A61K 9/2

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/50 , A61K 9/14 , A61K 9/22 , A61K 9/26 , A61K 9/48 , A61K 9/52 , A61P 15/18 , A61P 25/00 , A61P 29/00 , A61P 3/10 , A61P 31/04 , A61P 31/10 , A61P 31/12 , A61P 7/02

Ipc: A61K 9/50 (2006.01), A61K 9/52 (2006.01), A61K 9/1

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Z Decision to grant cancelled [chapter 9.1.1 patent gazette]

Free format text: REF. RPI 2315, DE 19/05/2015

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 25 DA LPI

B25A Requested transfer of rights approved

Owner name: FLAMEL IRELAND LIMITED (IE)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/10/2022